Gleevec (Imatinib) Unknown


Indications and Reactions:

Role Indications Reactions
Primary
Chronic Myeloid Leukaemia 45.9%
Gastrointestinal Stromal Tumour 24.8%
Gastric Cancer 7.2%
Soft Tissue Cancer 6.6%
Acute Lymphocytic Leukaemia 4.8%
Gastrointestinal Carcinoma 1.7%
Leukaemia 1.7%
Neoplasm Malignant 1.4%
Acute Myeloid Leukaemia 0.7%
Chronic Leukaemia 0.7%
Neoplasm 0.7%
Rectal Cancer 0.7%
Soft Tissue Neoplasm 0.7%
Eosinophilia 0.3%
Gastrointestinal Neoplasm 0.3%
Liver Disorder 0.3%
Malignant Anorectal Neoplasm 0.3%
Malignant Mast Cell Neoplasm 0.3%
Neuroendocrine Carcinoma Of The Skin 0.3%
Paraproteinaemia 0.3%
Neoplasm Recurrence 16.7%
Neoplasm Progression 10.6%
Vomiting 10.6%
Pneumonia 7.1%
White Blood Cell Count Decreased 6.1%
Neoplasm Malignant 5.6%
Weight Increased 5.1%
Leukaemia Recurrent 4.5%
White Blood Cell Count Increased 4.5%
Pleural Effusion 3.5%
Fatigue 3.0%
Malignant Neoplasm Progression 3.0%
Renal Failure 3.0%
Urinary Tract Infection 3.0%
Weight Decreased 3.0%
Pulmonary Oedema 2.5%
Chronic Myeloid Leukaemia 2.0%
Drug Ineffective 2.0%
Myocardial Infarction 2.0%
Nausea 2.0%
Secondary
Chordoma 100.0%
Disease Progression 100.0%
Concomitant
Gastrointestinal Stromal Tumour 100.0%
White Blood Cell Count Decreased 100.0%

Drug Data